Advertisement
Advertisement
U.S. markets close in 4 hours 5 minutes
Advertisement
Advertisement
Advertisement
Advertisement

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
77.67+2.54 (+3.38%)
As of 11:55AM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • F
    Fayez Rasuli
    Wow what a great report! Back to 220$
  • T
    Tom
    Pfizer buying GBT which just treats symptoms of SCD for $5.5 billion.
    CRSP must be worth over $300 as it has 100% cure rate for Sickle Cell diseases and 7 other clinical programs.
  • B
    Brian
    Speculators woke up and said growth is out of favor. They assume borrowing cost will keep going up because of the new spending bill. I think most of the top Crispr companies are in good shape. I guess they need their day to shine. I can not wait till the cures to start rolling in.
  • j
    john
    if global blood is bought out by PFE for the rumored price of 5b what do you think this is worth - 10 to 15m easy bec of the product pipeline...........
  • R
    Roger
    Not a huge fan of charting, but the 50 dma just crossed the 200 on 8/3 - bullish.
    The upper Bollinger band sits today around $85 and recent high is $87. A move through both - also bullish, 15%+.
  • C
    CCN
    CRISPR Therapeutics' Base Can Support Further Price Gains
    Let's look at the charts and indicators.
    By BRUCE KAMICH Aug 08, 2022 | 10:58 AM EDT

    Bottom line strategy: Traders who went long following our July 1 update should continue to hold those positions. The $88-$102 area is our price target.
  • C
    Cnote
    Loading up!…Stage is set for next big move
  • B
    Brian
    These are the only companies offering something more important than money, life. Just ask an old billionaire what they would pay for a couple of extra healthy years.
  • O
    Offer
    $EDIT conversation
    ARKG started selling $CRSP and $NTLA. I wonder if she will dump everything like EDIT or if she is just playing the volatility.
    Bullish
  • C
    Charlie
    A very sweet rise in price this morning when I turned on my computer. $82.03 as I type. We are seeing institutions buying most likely and most of those will add over time. When thousands more retail investors find this stock....watch CRSP climb. !!!
    Bullish
  • C
    CCN
    CRISPR Therapeutics AG (CRSP) Has Great Growth Outlook For 2022
    Isaac Mitchell
    August 10, 2022
    Technologies
    CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 1.93 and has seen 1.58 million shares traded in the last trading session. The company, currently valued at $5.64B, closed the last trade at $75.13 per share which meant it lost -$6.26 on the day or -7.69% during that session. The CRSP stock price is -89.86% off its 52-week high price of $142.64 and 43.42% above the 52-week low of $42.51. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.24 million shares traded. The 3-month trading volume is 2.01 million shares.

    CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
    Sporting -7.69% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 08/09/22 when the CRSP stock price touched $75.13 or saw a rise of 10.67%. Year-to-date, CRISPR Therapeutics AG shares have moved -0.86%, while the 5-day performance has seen it change -1.59%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed 1.93%. Short interest in the company has seen 11.53 million shares shorted with days to cover at 3.91.
  • G
    George
    The waiting room is jammed. No seats left.
  • C
    CCN
    Qube Research & Technologies Ltd lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 189.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 81,592 shares of the company’s stock after purchasing an additional 53,414 shares during the quarter. Qube Research & Technologies Ltd owned 0.11% of CRISPR Therapeutics worth $5,122,000 at the end of the most recent reporting period.

    Other large investors have also made changes to their positions in the company. Capital Impact Advisors LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth about $26,000. Elkhorn Partners Limited Partnership lifted its position in CRISPR Therapeutics by 180.0% during the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock worth $27,000 after buying an additional 225 shares in the last quarter. IronBridge Private Wealth LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth about $30,000. First PREMIER Bank acquired a new position in CRISPR Therapeutics during the 1st quarter worth about $31,000. Finally, Allworth Financial LP lifted its position in CRISPR Therapeutics by 443.8% during the 1st quarter. Allworth Financial LP now owns 609 shares of the company’s stock worth $38,000 after buying an additional 497 shares in the last quarter. Institutional investors own 56.12% of the company’s stock.
  • T
    Tom
    At $77 a share with $32 in cash , shares ex cash are $45 . This is market cap with cash of $5.5 billion. For this you get CTX001 valued Now by Vertex at $20 billion. Crazily low valuation contorted by shorts. With BLA soon and FDA approval early next year, this is a 50-100 bagger in next few years. CRSPR is future of treating and curing diseases and paying 2 cents on the dollar now for future valuation.
  • K
    Karlos
    Nice tick up tdy... only 50% down in my holdings fully aware this could turn in an instant on good news. Prepared to hold for the next 5 years. Maybe I'll buy a Tesla with my returns.. let's see. Gl to all longs out there wish you all well.
  • T
    Tom
    100,000 SCD patients a year and 50,000 Thalassemia major patients= 150,000 patients. At $1-million per patient to cure, which costs less than taking care of these patients for 45 years. if just 10% get treated initially this is $15 billion in revenues . Numbers speak for themselves and shares will follow. No longer, a dream, but reality for these deserving patients to have normal lives.
  • P
    Phil
    VRTX pile of cash continues to build. Wondering when they buy CRSP.
  • T
    Tom
    Follow the 100% cure rate for SCD . Will be baby google of biotech.
Advertisement
Advertisement